A top General Motors executive said he doubts Japanese auto makers would use the weaker yen to launch a price war in the U.S. this summer even as they face softer revenue at home.

FDA staff said a proposed sleep drug from Merck was effective, but questioned the safety of the product's higher doses. Merck is seeking FDA approval of a drug called suvorexant to treat insomnia. The product will be reviewed Wednesday by an FDA advisory committee.

Plains Exploration & Production's shareholders Monday approved a $6.5 billion merger with Freeport-McMoRan Copper & Gold, overcoming earlier pressure to reject the deal.

Next month, iShares, the largest ETF provider by assets, will do something it hasn't done in more than a decade: close one of its 290 ETFs. Experts say that highlights the complications that arise when funds drop out.

A new wave of private firms that cater to clients' every imaginable financial need are increasingly courting the merely wealthy. Here's what they offer.

The Intelligent Investor: A few investors have taken the bold step of investing directly in their adviser's firm. What could possibly go wrong?

To earn yields of 5% or more, investors are turning to more complex fare, such as high-yield corporate bonds, preferred stocks and real-estate investment trusts.

Most people still take their Social Security benefits as soon as they possibly can and many of them are leaving money on the table.

Personal aptitudes and attitudes like being a good listener and communicator strongly influence likability and workplace relationships.